With A $1.2 Billion Hammer, The Federal Trade Commission Closes Loophole To Prevent Generic Drugs
This morning, the U.S. Federal Trade Commission drew blood: Teva Pharmaceuticals will pay $1.2 billion to reimburse insurers, drug wholesalers, and pharmacies who paid full price for the Provigil, produced by Cephalon, a company Teva bought in 2011, because Cephalon had paid generic drugmakers to delay launching cheaper versions of the blockbuster drug.
Hey, check out all the research scientist jobs. Post your resume today!
Hey, check out all the research scientist jobs. Post your resume today!